DOI QR코드

DOI QR Code

Safety Assessment of Intravenous Administration of Trastuzumab in 100ml Saline for the Treatment of HER2-Positive Breast Cancer Patients

  • Abe, Hajime (Breast Center, Bell Land General Hospital) ;
  • Mori, Tsuyoshi (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Kawai, Yuki (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Tomida, Kaori (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Yamazaki, Keiichi (Breast Center, Bell Land General Hospital) ;
  • Kubota, Yoshihiro (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Umeda, Tomoko (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Tani, Tohru (Department of Surgery, Shiga University of Medical Science)
  • Published : 2013.08.30

Abstract

Background: The infusion rate is considered to affect incidence and severity of infusion reactions (IRs) caused by protein formulations. Trastuzumab (TRS) is approved for 90-minute infusion as the initial dose followed by 30-minute infusion with 250 ml saline. In the study, we evaluated the safety of TRS intravenously administered over 30 minutes with 100 ml saline to reduce burden of patients, safety of infusion with 250 ml saline already being established. Materials and Methods: Women with HER2 positive breast cancer, ${\geq}18$ years and ${\geq}55%$ left ventricular ejection fraction (LVEF), were registered in the study. Patients received 8mg/kg of TRS 250 ml over 90 minutes followed by 6mg/kg of TRS 100ml over 30 minutes in a three-week cycle. Results: A total of 31 patients were recruited, 24 for adjuvant therapy and seven with metastases. The median age was 59 years (range 39 to 82). The total number of TRS doses ranged from 5 to 17 with the median of 15. Mild IR occurred in two patients at the first dose. However, no IR was observed after reducing to 100 ml saline. No decrease of LVEF, increase of serum brain natriuretic peptide or any other adverse events were reported. Conclusions: Intravenous infusion of TRS with 100 ml saline over 30 minutes in breast cancer patients can be considered safe based on results from the study. It can be given on an outpatient basis as with the currently recommended dilution in 250 ml saline.

Keywords

Trastuzumab;infusion reaction;breast cancer;100 ml saline

References

  1. Tan-Chiu E, Yothers G, Romond E, et al (2005). Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol, 23, 7811-9. https://doi.org/10.1200/JCO.2005.02.4091
  2. Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81 https://doi.org/10.1016/S1053-4296(03)00031-6
  3. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 28, 687-97
  4. Bardin C, Astier A, Vulto A, et al (2011). Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr, 69, 221-31. https://doi.org/10.1016/j.pharma.2011.07.002
  5. Cook-Bruns N (2001). Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology, 61, 58-66. https://doi.org/10.1159/000055403
  6. Halyard MY, Pisansky TM, Dueck AC, et al (2009). Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol, 27, 2638-44. https://doi.org/10.1200/JCO.2008.17.9549
  7. Lenz HJ (2007). Management and preparedness for infusion and hypersensitivity reactions. The Oncologist, 12, 601-9. https://doi.org/10.1634/theoncologist.12-5-601
  8. Leyland-Jones B, Gelmon K, Ayoub JP (2003). Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol, 21, 3965-71. https://doi.org/10.1200/JCO.2003.12.109
  9. Owens MA, Horten BC, Da Silva MM (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9. https://doi.org/10.3816/CBC.2004.n.011
  10. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer; correlation of relapse and survival with amplification of the HER2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  11. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. https://doi.org/10.1056/NEJM200103153441101
  12. Slamon D, Eiermann W, Robert N, et al (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 365, 1273-83. https://doi.org/10.1056/NEJMoa0910383
  13. Suter TM, Procter M, van Veldhuisen DJ, et al (2007). Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol, 25, 3859-65. https://doi.org/10.1200/JCO.2006.09.1611

Cited by

  1. Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1643